FeesSafety
Pluang+

Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Market News
20 Nov 2026, 01:45 WIB
The Motley Fool
View Source
Bullish
Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Johnson & Johnson's investigational prostate cancer drug JNJ-6143 demonstrated a 75% overall response rate in a Phase 1 trial involving patients with advanced metastatic castration-resistant prostate cancer. This promising early result highlights the potential of JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, to become a strong new treatment option. While further clinical trials are needed, the success underscores Johnson & Johnson's robust drug pipeline and innovation focus, supported by recent drug launches and a strategic spin-off of its consumer health division. The company also remains attractive for income investors as a Dividend King with 64 years of consecutive dividend increases.

As of Nov 20, 2026 07:02 WIB, Johnson & Johnson shares trade at USD 266.85 on Pluang, down 2.15% for the day with a market cap of $656.47 billion. Despite the recent dip, the company remains a Dividend King with a 1.97% dividend yield, attracting a balanced mix of buyers and sellers, with 52% of order activity on Pluang being buys. This investor interest coincides with the positive clinical trial news, highlighting the company's ongoing innovation in healthcare.

More News (JNJ)

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
29 minutes ago
3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow dividend stocks ideal for retirement income due to their long track records and diverse business models. Johnson & Johnson leads with 64 consecutive years of dividend incr...

Market News
Bullish
8 hours ago
Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow Jones dividend stocks for reliable retirement income. Each company has a long history of dividend payments, with Johnson & Johnson boasting 64 consecutive years of increas...

Market News
Bullish
15 hours ago
Invest $25K in 4 dividend stocks to earn about $799 annually for retirement income.

Invest $25K in 4 dividend stocks to earn about $799 annually for retirement income.

Investing $25,000 evenly across four dividend-paying stocks—Johnson & Johnson, Procter & Gamble, Exxon Mobil, and Realty Income—can generate approximately $799 in annual passive income. These companies span healthcare, consumer staples, energy, and r...

Bullish
1 day ago
Law firm investigates Johnson & Johnson for potential securities fraud after Q3 earnings miss.

Law firm investigates Johnson & Johnson for potential securities fraud after Q3 earnings miss.

Pomerantz LLP is investigating Johnson & Johnson and some of its officers for possible securities fraud following the company's disappointing Q3 2026 financial results. J&J reported net earnings of $210 million, heavily impacted by large charges rela...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App